The revenue beat and raised guidance are positive, but the GAAP EPS miss, declining Adjusted EBITDA, deeply negative FCF, and COO departure create a mixed picture. Watch the Q2 2026 call for evidence that the $12M in elevated labor costs normalize and that the new capitated contract drives margin recovery. The $1.1B refinancing reduces near-term debt risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $11.75entry
- T+1 · 7mo ago −2.81%α −4.19% · $11.42
- T+5 · 6mo ago −4.26%α −6.24% · $11.25
- T+20 · 6mo ago −17.87%α −22.83% · $9.65
- T+60 · 4mo ago −9.11%α −11.85% · $10.68
Price Chart
How similar events traded
Executive Summary
AdaptHealth reported Q1 2026 revenue of $819.8M (+5.4% YoY), beating the $796.6M consensus, but GAAP EPS was -$0.12, a miss vs the $0.01 consensus. Adjusted EBITDA declined 5.3% to $121.2M and free cash flow was deeply negative at -$27.5M. Revenue guidance was raised by $10M to $3.45B-$3.52B, but EBITDA and FCF guidance were maintained. The COO was terminated and replaced internally. The combination of a GAAP EPS miss, declining profitability, negative FCF, and a C-suite departure tempers the positive revenue beat and guidance raise.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $819.8M, +5.4% YoY from $777.9M, above $796.6M consensus
- GAAP diluted EPS -$0.12 vs consensus $0.01, a significant miss
- Net loss attributable to AdaptHealth widened to -$16.0M from -$7.2M YoY
- Adjusted EBITDA fell 5.3% to $121.2M from $127.9M; margin contracted to 14.8% from 16.4%
- Free cash flow was -$27.5M vs -$0.1M YoY, driven by $121.2M in capex
- FY 2026 revenue guidance raised by $10M to $3.45B-$3.52B; EBITDA and FCF guidance maintained
- COO Toby Scott Barnhart terminated May 4, 2026; replaced by Daniel McFadden (internal)
- Completed $1.1B refinancing of senior secured credit facility in April 2026
- Organic revenue growth of 9.1%, with growth across all four segments
- Cash balance fell to $48.0M from $106.1M at year-end 2025
Financial Impact
Revenue beat of ~$23M vs consensus but GAAP EPS miss of -$0.13; Adjusted EBITDA down $6.7M YoY; FCF swing of -$27.4M
Risk Factors
- GAAP profitability continues to deteriorate, net loss widened 123% YoY
- Free cash flow deeply negative at -$27.5M, requiring debt or equity to fund capex
- COO termination could signal operational execution challenges with the new capitated contract
- Cash balance halved to $48M, reducing financial flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030120 |
| Document: ahco-20260505.htm | 0001628280-26-030120 |
| Document: 0001628280-26-030120-index-headers.html | 0001628280-26-030120 |
| Document: 0001628280-26-030120-index.html | 0001628280-26-030120 |
| Document: 0001628280-26-030120.txt | 0001628280-26-030120 |
| 8-K Data (Synthetic) | 0001628280-26-030120 |
Track record
20 reports on AHCO
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +47.49% at T+60 after the Jul 2, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.80 Now $7.73 −0.90% settles Nov 18
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $7.89 Now $7.73 −2.03% settles Nov 17
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $7.87 to $7.66 Now $7.73 −1.78% ▼ −2.67% −2.31% vs SPY
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $7.35 to $7.72 Now $7.73 +5.17% ▲ +5.03% +5.40% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $7.35 to $7.72 Now $7.73 +5.17% ▲ +5.03% +5.40% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $7.33 to $7.35 Now $7.73 +5.46% ▲ +0.27% −2.09% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $7.41 to $7.33 Now $7.73 +4.32% ▼ −1.08% −1.39% vs SPY
- Nov 3, 202613d ago 8-K Mixed 6/10 Entry $6.28 to $7.31 Now $7.73 +23.09% ▲ +16.40% +14.75% vs SPY
- Oct 29, 202619d ago Court Ruling Neutral 2/10 Entry $5.81 to $5.91 Now $7.73 +33.05% ▲ +1.72% +2.20% vs SPY
- Oct 13, 20264w ago SC 13G/A Bearish 4/10 Entry $6.33 to $6.25 Now $7.73 −22.12% ▲ +1.26% +0.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers